Prevalence of High Tumor Mutational Burden and Association With Survival in Patients With Less Common Solid Tumors-Reference-Cited by-同舟云学术

Prevalence of High Tumor Mutational Burden and Association With Survival in Patients With Less Common Solid Tumors

Published:2020-10-29 Issue:10 Volume:3 Page:e2025109
ISSN:2574-3805
Container-title:JAMA Network Open
language:en
Short-container-title:JAMA Netw Open

Author:

Shao Changxia¹,Li Gerald²,Huang Lingkang¹,Pruitt Scott¹,Castellanos Emily³,Frampton Garrett²,Carson Kenneth R.³,Snow Tamara³,Singal Gaurav²,Fabrizio David²,Alexander Brian M.²,Jin Fan¹,Zhou Wei¹

Affiliation:

1. Merck and Co, Kenilworth, New Jersey

2. Foundation Medicine, Cambridge, Massachusetts

3. Flatiron Health, New York, New York

Publisher

American Medical Association (AMA)

Subject

General Medicine

Link

https://jamanetwork.com/journals/jamanetworkopen/articlepdf/2772345/shao_2020_oi_200819_1603374746.00517.pdf

Reference33 articles.

1. Tumor mutational load predicts survival after immunotherapy across multiple cancer types.;Samstein;Nat Genet,2019

2. Association of patient characteristics and tumor genomics with clinical outcomes among patients with non–small cell lung cancer using a clinicogenomic database.;Singal;JAMA,2019

3. PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers.;Yarchoan;JCI Insight,2019

4. Signatures of mutational processes in human cancer.;Alexandrov;Nature,2013

5. TGFß attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.;Mariathasan;Nature,2018

Cited by 103 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Overall survival prediction of gastric cancer using the gene signature of CT-detected extramural venous invasion combined with M2 macrophages infiltration;Journal of Translational Medicine;2024-09-09

2. Efficacy and safety of camrelizumab, apatinib, and capecitabine combination therapy in advanced biliary tract cancer: a phase 2, nonrandomized, prospective study;The Oncologist;2024-08-05

3. Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden;Journal for ImmunoTherapy of Cancer;2024-08

4. Recent Advances in Immunotherapy for Advanced Biliary Tract Cancer;Current Treatment Options in Oncology;2024-07-27

5. Advanced Cholangiocarcinoma With High Tumor Mutation Burden Achieving Complete Response to Immune Check Point Inhibitor;Anticancer Research;2024-06-26